CRISPR Therapeutics reports promising Phase 1 clinical data for CTX310™, with significant triglyceride and LDL reductions, and updates on other programs. CRISPR Therapeutics announced promising new ...
How CRISPR and functional genomics are used to establish causality, understand disease mechanisms and guide early drug ...
Nobel laureate Jennifer Doudna, PhD; Matthew Porteus, MD, PhD, and Rodolphe Barrangou, PhD—offer their views on the commercial potential and challenges of genome editing following a rollercoaster 2025 ...
CRISPR Therapeutics AG (NASDAQ:CRSP) reported new topline study results on Wednesday to establish risk factors for atherosclerotic heart disease. The company disclosed data regarding the first 10 ...
-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% ...
-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in ...
Oceanic ecosystems are increasingly threatened by global warming, which causes coral bleaching, species migration and, ...
1don MSN
Citizens Maintains Outperform Rating On CRISPR Therapeutics (CRSP) Citing Undervalued Pipeline
CRISPR Therapeutics (NASDAQ:CRSP) is one of the stocks that should double by 2030. On January 30, Citizens maintained an ...
Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results